ResMed Inc. (RMD) — 分析摘要
ResMed Inc.(RMD)的市值为28.79十亿美元,最近一年的营收同比增长了+9.8%。净利润率为27.2%。当前市盈率为18.9倍。
核心要点
- 营收同比变化+9.8%
- 净利润率27.2%
- 市盈率18.9倍
与SURGICAL & MEDICAL INSTRUMENTS & APPARATUS板块的其他公司相比,RMD的营收增长为+9.8%,市盈率为18.9倍。
ResMed Inc. (RMD)
更新 — ET · 来源 POLYGON
红旗与风险提示无重大红旗
基于最新财报,没有触发重大的信用、利润率或趋势红旗。
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
行业
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
员工人数
10,600
总部
SAN DIEGO, CA
Exchange
XNYS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
年度每股股息
$2.40
股息收益率
1.24%
股息历史
免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。